{
    "nct_id": "NCT05662241",
    "official_title": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with IgG4-Related Disease (INDIGO)",
    "inclusion_criteria": "1. Males and females, â‰¥ 18 years of age\n2. Clinical diagnosis of IgG4-RD\n3. Patients must meet the 2019 ACR/EULAR Classification Criteria for IgG4-RD\n4. Patients must have active IgG4-RD signs/symptoms (i.e., flare) that require the initiation of GC therapy or the increase in background long-term GC therapy\n5. Other inclusion criteria apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Has disease in only 1 organ system whose primary manifestation is fibrosis\n2. Has received prednisone equivalent given orally at a dose greater than 60 mg/day within the 4 weeks prior to screening or during screening\n3. Has received a non-biologic, disease-modifying anti-rheumatological drug or immunosuppressive agent other than GCs within the 4 weeks prior to screening\n4. Has received an investigational treatment or direct medical intervention on another clinical study within 12 weeks or < 5 half-lives of the investigational treatment, whichever is shorter, prior to screening\n5. Has received live vaccine or live therapeutic infectious agent within the 2 weeks prior to screening\n6. Active tuberculosis or high risk for tuberculosis; hepatitis C infection in absence of curative treatment; evidence of hepatitis B infection\n7. Use of B cell depleting or targeting agents within 6 months of randomization\n8. Other exclusion criteria apply",
    "miscellaneous_criteria": ""
}